30-01-2013

Specialised Therapeutics Australia announced that a phase III clinical trial of breast cancer drug ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved ...

more

21-12-2012

Biotron Limited (BIT) has completed the clinical stage of a landmark phase 1b/2a proof-of-concept human trial of its lead HIV drug candidate, BIT225. The placebo-controlled, double-blinded study was undertaken at a clinical trial unit in Bangkok, Thailand. Patients enrolled in the trial were ...

more

20-12-2012

Viralytics Limited (VLA) in its US-based Phase II melanoma trial of its virotherapy candidate CAVATAKTM has achieved an interim efficacy subgoal of three Objective Responses (OR). This follows a recent review by the independent Data Monitoring Committee (DMC) of the trial. In the Phase II ...

more

21-11-2012

Avita Medical Ltd. has initiated a multicenter randomized control study on the use of ReCell® Spray-On Skin® in the treatment of venous leg ulcers. Up to five European centres from countries including the United Kingdom, Germany, France and Denmark will participate in the study.Lower limb ...

more

16-11-2012

Starpharma Vice President Dr Malcolm McColl has been appointed Chief Executive Officer of Viralytics Limited.From 2010 Dr McColl was Vice-President of Business Development at Starpharma where he was responsible for completion of partnering transactions with global and regional companies. He ...

more

Acquisition provides Bionomics with cancer stem cell technology and antibody drug candidates

18-09-2012

Bionomics Limited has acquired San Diego-based private biotechnology company Eclipse Therapeutics Inc in a scrip-based US$10 million deal. With consideration of approximately 23.9 million shares at 41.76 cents per share, Eclipse shareholders, that include NASDAQ-listed Biogen Idec, will own ...

more

25-06-2012

A new therapy to treat a common hospital superbug infection Clostridium difficile, will soon be available to Australian & New Zealand patients. Specialised Therapeutics Australia Pty, Ltd. (STA) has entered into an exclusive distribution & license agreement with US based Optimer ...

more

24-05-2012

Bionomics Limited has launched a Phase I/II clinical trial of its vascular disrupting agent BNC105 in women with ovarian cancer. It is anticipated that up to 134 women will be enrolled at 18 sites across Australia, New Zealand and the United States, including sites in Indiana and Wisconsin. ...

more

02-05-2012

Hatchtech Pty Ltd has appointed Dr Ross Macdonald as its Chief Executive Officer. The company has also secured additional capital, bringing total funds raised in the current round to AUD7.8 million.The appointment of the CEO and the completion of the latest financing round, enables ...

more

13-04-2012

RMIT University and vivoPharm jointly announced the sale of RMIT Drug Discovery Technologies Pty Ltd (RDDT) to vivoPharm Pty Ltd. As a result of the share based transaction RMIT will become a 20% shareholder in vivoPharm. RDDT is a Good Laboratory Practice (GLP)-compliant pre-clinical ...

more